Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Sponsor
ShengFa Su
Study ID
NCT03613753
Phase
PHASE2
Status
Unknown

Conditions

  • Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.

Key Dates

Start date
Jun 1, 2018
Status verified
Feb 2020
Primary completion
Jun 1, 2020
Completion
Jun 1, 2021

Study Design

Enrollment
72 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Chemotherapy:irinotecan plus lobaplatin
  • Active Comparator: Arm B
    Chemotherapy:irinotecan

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: >4 weeks post treatment ]

Central Contacts

Related Studies